---
title: "Tranche Update on RemeGen Co., Ltd.'s Equity Buyback Plan announced on December 15, 2025."
description: "From January 1, 2026 to January 20, 2026, the company has repurchased 194,144 shares, representing 0.04% for CNY 20 million. With this, the company has completed the repurchase of 194,144 shares, repr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273231494.md"
published_at: "2026-01-21T12:40:28.000Z"
---

# Tranche Update on RemeGen Co., Ltd.'s Equity Buyback Plan announced on December 15, 2025.

> From January 1, 2026 to January 20, 2026, the company has repurchased 194,144 shares, representing 0.04% for CNY 20 million. With this, the company has completed the repurchase of 194,144 shares, representing 0.04% for CNY 20 million under the buyback announced on December 15, 2025.

From January 1, 2026 to January 20, 2026, the company has repurchased 194,144 shares, representing 0.04% for CNY 20 million. With this, the company has completed the repurchase of 194,144 shares, representing 0.04% for CNY 20 million under the buyback announced on December 15, 2025.

### Related Stocks

- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [09995.HK - REMEGEN](https://longbridge.com/en/quote/09995.HK.md)
- [688331.CN - RemeGen](https://longbridge.com/en/quote/688331.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) |
| 埃隆·馬斯克的 Neuralink 在中國激發了腦機接口技術的競賽 | Neuralink，由埃隆·馬斯克創立，正在推動中國腦機接口（BCI）發展的熱潮，像 NeuroXess 這樣的初創公司迅速進入人體試驗階段。NeuroXess 於 2021 年成立，已經在患者身上測試植入物。中國政府已將 BCI 列為戰略 | [Link](https://longbridge.com/en/news/276460367.md) |
| 榮昌生物預計 2025 年淨利潤將達到人民幣 7.16 億元，收入將增長 89% | 榮昌生物預計 2025 年的淨利潤為人民幣 7.16 億元，主要受益於 89% 的收入激增。公司將這一改善歸因於更好的成本結構、提高的毛利率和降低的銷售費用。排除非經常性項目後，榮昌生物預計當年的淨利潤將實現扭轉，反映出業務表現的顯著提升。 | [Link](https://longbridge.com/en/news/274301011.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.